Masimo (NASDAQ:MASI) Releases FY25 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.90-$5.10 for the period, compared to the consensus EPS estimate of $4.74. Masimo also updated its FY 2024 guidance to 4.100-4.100 EPS.

Masimo Trading Up 1.4 %

Shares of NASDAQ MASI opened at $172.29 on Friday. The business’s 50 day moving average is $169.23 and its two-hundred day moving average is $140.13. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo has a 1-year low of $101.61 and a 1-year high of $180.97. The stock has a market capitalization of $9.22 billion, a P/E ratio of 118.82 and a beta of 1.01.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.63 earnings per share. As a group, research analysts expect that Masimo will post 4.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Raymond James upped their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Thursday. BTIG Research boosted their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Wells Fargo & Company boosted their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $179.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.